StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

Investment analysts at StockNews.com started coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued to clients and investors on Friday. The brokerage set a “strong-buy” rating on the stock.

Separately, Truist Financial boosted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Fresenius Medical Care Price Performance

NYSE:FMS opened at $19.54 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The firm has a fifty day simple moving average of $20.32 and a 200 day simple moving average of $20.17. Fresenius Medical Care has a 1-year low of $16.46 and a 1-year high of $22.76. The stock has a market capitalization of $11.47 billion, a PE ratio of 21.96, a P/E/G ratio of 1.11 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last issued its earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The company had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. On average, research analysts expect that Fresenius Medical Care will post 1.52 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care

Several large investors have recently modified their holdings of FMS. Creative Planning lifted its position in Fresenius Medical Care by 18.9% during the second quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after purchasing an additional 6,373 shares during the period. Wulff Hansen & CO. lifted its holdings in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares during the period. QRG Capital Management Inc. lifted its holdings in shares of Fresenius Medical Care by 19.5% during the 1st quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock worth $1,048,000 after acquiring an additional 8,870 shares during the period. SG Americas Securities LLC boosted its position in shares of Fresenius Medical Care by 50.0% during the 1st quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock worth $294,000 after acquiring an additional 5,078 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in Fresenius Medical Care by 8.5% in the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after acquiring an additional 1,207 shares during the last quarter. 8.25% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.